Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

436 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prognostic power assessment of clinical parameters to predict neoadjuvant response therapy in HER2-positive breast cancer patients: A machine learning approach.
Fanizzi A, Latorre A, Bavaro DA, Bove S, Comes MC, Di Benedetto EF, Fadda F, La Forgia D, Giotta F, Palmiotti G, Petruzzellis N, Rinaldi L, Rizzo A, Lorusso V, Massafra R. Fanizzi A, et al. Among authors: lorusso v. Cancer Med. 2023 Nov;12(22):20663-20669. doi: 10.1002/cam4.6512. Epub 2023 Oct 31. Cancer Med. 2023. PMID: 37905688 Free PMC article.
Robustness Evaluation of a Deep Learning Model on Sagittal and Axial Breast DCE-MRIs to Predict Pathological Complete Response to Neoadjuvant Chemotherapy.
Massafra R, Comes MC, Bove S, Didonna V, Gatta G, Giotta F, Fanizzi A, La Forgia D, Latorre A, Pastena MI, Pomarico D, Rinaldi L, Tamborra P, Zito A, Lorusso V, Paradiso AV. Massafra R, et al. Among authors: lorusso v. J Pers Med. 2022 Jun 10;12(6):953. doi: 10.3390/jpm12060953. J Pers Med. 2022. PMID: 35743737 Free PMC article.
A machine learning ensemble approach for 5- and 10-year breast cancer invasive disease event classification.
Massafra R, Comes MC, Bove S, Didonna V, Diotaiuti S, Giotta F, Latorre A, La Forgia D, Nardone A, Pomarico D, Ressa CM, Rizzo A, Tamborra P, Zito A, Lorusso V, Fanizzi A. Massafra R, et al. Among authors: lorusso v. PLoS One. 2022 Sep 19;17(9):e0274691. doi: 10.1371/journal.pone.0274691. eCollection 2022. PLoS One. 2022. PMID: 36121822 Free PMC article.
Analyzing breast cancer invasive disease event classification through explainable artificial intelligence.
Massafra R, Fanizzi A, Amoroso N, Bove S, Comes MC, Pomarico D, Didonna V, Diotaiuti S, Galati L, Giotta F, La Forgia D, Latorre A, Lombardi A, Nardone A, Pastena MI, Ressa CM, Rinaldi L, Tamborra P, Zito A, Paradiso AV, Bellotti R, Lorusso V. Massafra R, et al. Among authors: lorusso v. Front Med (Lausanne). 2023 Feb 2;10:1116354. doi: 10.3389/fmed.2023.1116354. eCollection 2023. Front Med (Lausanne). 2023. PMID: 36817766 Free PMC article.
Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experience.
Ciccarese M, Fabi A, Moscetti L, Cazzaniga ME, Petrucelli L, Forcignanò R, Lupo LI, De Matteis E, Chiuri VE, Cairo G, Febbraro A, Giordano G, Giampaglia M, Bilancia D, La Verde N, Maiello E, Morritti M, Giotta F, Lorusso V, Latorre A, Scavelli C, Romito S, Cusmai A, Palmiotti G, Surico G. Ciccarese M, et al. Among authors: lorusso v. Breast Cancer Res Treat. 2017 Jun;163(3):587-594. doi: 10.1007/s10549-017-4213-9. Epub 2017 Mar 28. Breast Cancer Res Treat. 2017. PMID: 28353061
A Clinical Decision Support System for Predicting Invasive Breast Cancer Recurrence: Preliminary Results.
Massafra R, Latorre A, Fanizzi A, Bellotti R, Didonna V, Giotta F, La Forgia D, Nardone A, Pastena M, Ressa CM, Rinaldi L, Russo AOM, Tamborra P, Tangaro S, Zito A, Lorusso V. Massafra R, et al. Among authors: lorusso v. Front Oncol. 2021 Mar 11;11:576007. doi: 10.3389/fonc.2021.576007. eCollection 2021. Front Oncol. 2021. PMID: 33777733 Free PMC article.
436 results